Single-agent ICIs that target the PD-1/PD-L1 pathways, such as pembrolizumab, nivolumab, cemiplimab, and atezolizumab, have significantly improved OS and PFS in advanced NSCLC patients with BM [30,31]. The gene discussed is CD274; the disease is non-small cell lung carcinoma.